Pune: The chief of city based Serum Institute of India believes that the country is at least 6 months away from their vaccine.
The company's CEO Adar Poonawalla reportedly explained that their researchers were focusing on a safe and effective vaccine rather than rushing through crucial research, development and testing procedures.
"Once we are confident of a safe and good vaccine for India and the world. We will certainly announce it when we are licensed by the Drug Controller (DCGI), but that is still at least six months away from now," he explained in a recent interaction around the sidelines of the launch of CompactXL a compact diagnostics machine by MyLab Discovery Solutions.
Recently, the Indian Council of Medical Research received bad-press owing to a policy suggesting a deadline of August 15'2020 to Covaxin, a contender which could become a successful vaccine. Covaxin' phase 1 human trials have commenced.
The CEO added, "End of the year, we are hoping to have a vaccine. So we will discuss once the phase three trials for the product come about. Recently, there was news about another vaccine candidate which was being rushed. We do not want to rush anything. We want to emphasis on safety and efficacy..."
According to Poonawalla testing remained crucial to controlling Covid infections. He remarked, "There is a fear that what will happen if the number of positive patients increases. I would like to say that there is no harm if the number increases as it will help us detect people," he added.
The Serum Institute of India has partnered with Oxford University on an Astrazeneca backed vaccine prototype. The research is currently in the phase II-III trials. Under the pact signed with British-Swedish pharma maker AstraZeneca, Serum Institute will supply 1 billion doses of the vaccine in India and other low and middle-income countries, with a commitment to provide 400 million before the end of 2020.